Vascular endothelial growth factor gene therapy - ViroMed

Drug Profile

Vascular endothelial growth factor gene therapy - ViroMed

Alternative Names: VMDA-3601

Latest Information Update: 13 Oct 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Dong-A Pharmaceutical; ViroMed Co Ltd
  • Class Cytokine genes; Gene therapies; Growth factors
  • Mechanism of Action Gene transference; Vascular endothelial growth factor A expression stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Peripheral arterial occlusive disorders

Most Recent Events

  • 13 Oct 2010 Discontinued - Phase-II for Peripheral arterial occlusive disorders in South Korea (IM)
  • 01 Aug 2007 VMDA 3601 is still in active development
  • 26 Jan 2004 Phase-II clinical trials in Peripheral arterial occlusive disorders in South Korea (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top